Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Prospective analysis of CEA, CA19.9, circulating DNA (cDNA) and circulating tumor cells (CTC) in patients (pts) treated for a metastatic colorectal cancer (mCRC)_Results of COCA-COLON study

Date

10 Oct 2016

Session

Poster display

Presenters

David Sefrioui

Citation

Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363

Authors

D. Sefrioui1, N. Vasseur2, E. Toure3, F. Blanchard3, J. Delacour2, C. Thill4, L. Beaussire2, A. Gillibert4, F. Ziegler5, A. Gangloff6, K. Bouhier-Leporrier7, A. Lefebvre7, A. Parzy8, M. Gallais8, F. Clatot9, A. Perdrix10, J. Sabourin3, T. Frebourg11, P. Michel6, F. Di Fiore9

Author affiliations

  • 1 Department Of Of Hepato-gastroenterology, IRON (equipe de recherche onco normande) within INSERM unit U1079., 76031 - Rouen/FR
  • 2 Institute For Biomedical Research And Innovation, Inserm U1079, University of Rouen, Rouen/FR
  • 3 Department Of Pathology, Rouen University Hospital, Rouen/FR
  • 4 Department Of Statistics, CHU Hôpitaux de Rouen-Charles Nicolle, Rouen/FR
  • 5 Institute Of Clinical Biology, Inserm Umr 1073, CHU Hôpitaux de Rouen-Charles Nicolle, Rouen/FR
  • 6 Department Of Of Hepato-gastroenterology, IRON (equipe de recherche onco normande) within INSERM unit U1079., Rouen/FR
  • 7 Department Of Hepatogastroenterology, CHU de Caen, Caen/FR
  • 8 Hepatogastroenterology, Centre Francois Baclesse, Caen/FR
  • 9 Medical Oncology, Centre Henri Becquerel, Rouen/FR
  • 10 Seine Maritime, Centre Henri Becquerel, 76000 - Rouen/FR
  • 11 Department Of Genetics, Rouen University Hospital, Rouen/FR
More

Resources

Background

CEA, CA19.9, cDNA and CTC have been reported as useful circulating markers in mCRC pts treated with chemotherapy (CT)-based regimen. We previously reported that CEA kinetic (threshold 0.05) was associated witht outcome [Iwanicki-Caron et al, J Clin Oncol 2008;26:3681-6]. We designed a prospective muticentric trial for CEA kinetic validation and to evaluate CA19.9, cDNA and CTC kinetics.

Methods

mCRC pts, PS 0-2, with CEA ≥ 5 µg/L or CA19.9 ≥ 30UI/mL, and who started a CT regimen were included. Plasma were collected taken from baseline (T0) to the fourth cycle for CEA and CA19.9 and at T0 and 6 weeks (W6) for cDNA and CTC kinetics. Cell-free DNA (cfDNA) was quantified by fluorimetric method, circulating tumour DNA (ctDNA) by Digital PCR and CTC (CTC+ vs CTC-) by ScreenCell(R) method. Primary endpoint was 3-months evaluation (control disease (CD) (response/stable) vs progressive disease (PD))) (RECIST 1.1) according to CEA kinetic. Secondary endpoints were progression-free survival (PFS) and overall survival (OS) according to baseline T0 median values (high vs low) of CEA, CA19.9, cfDNA, ctDNA, and CTC +/- and kinetics.

Results

A total of 200 mCRC pts were included with a median follow-up of 12 months (m) (range 1-41). Median CEA, CA19.9, cfDNA and ctDNA were 96 µg/L, 88 UI/mL, 24.2 ng/mL and 15.2% respectively. CtDNA was detected in 90% at T0 from the 95 KRAS/BRAF mutated tumours. A total of 54.7% were CTC+ at T0. CEA kinetic (≤0.05 threshold) was associated with response CD (90 vs 52%, p 

Conclusions

This prospective study confirmed that CEA kinetic is clinically relevant to monitor CT in mCRC. Results also highlight that CA19.9, cfDNA and ctDNA are also associated with outcome.

Clinical trial identification

Protocol : 2009/170/HP Clinical trial number : NCT01212510

Legal entity responsible for the study

CHU Rouen

Funding

Amgen, Roche and Merck (pharma) Fondation Pierre Durand et Marie-Therese Chevalier

Disclosure

D. Sefrioui, P. Michel, F. Di Fiore: Industrial partnership with Merck, Amgen and Roche. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings